IBDEI14F.m

IBDEI14F ; ; 01-FEB-2022

 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022

 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y

Q Q

 ;;^UTILITY(U,$J,358.3,18185,0)

 ;;=E11.620^^61^805^5

 ;;^UTILITY(U,$J,358.3,18185,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18185,1,3,0)

 ;;=3^DM Type 2 w/ Diab Dermatitis

 ;;^UTILITY(U,$J,358.3,18185,1,4,0)

 ;;=4^E11.620

 ;;^UTILITY(U,$J,358.3,18185,2)

 ;;=^5002655

 ;;^UTILITY(U,$J,358.3,18186,0)

 ;;=E11.36^^61^805^4

 ;;^UTILITY(U,$J,358.3,18186,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18186,1,3,0)

 ;;=3^DM Type 2 w/ Diab Cataract

 ;;^UTILITY(U,$J,358.3,18186,1,4,0)

 ;;=4^E11.36

 ;;^UTILITY(U,$J,358.3,18186,2)

 ;;=^5002642

 ;;^UTILITY(U,$J,358.3,18187,0)

 ;;=I10.^^61^806^1

 ;;^UTILITY(U,$J,358.3,18187,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18187,1,3,0)

 ;;=3^Essential/Primary Hypertension

 ;;^UTILITY(U,$J,358.3,18187,1,4,0)

 ;;=4^I10.

 ;;^UTILITY(U,$J,358.3,18187,2)

 ;;=^5007062

 ;;^UTILITY(U,$J,358.3,18188,0)

 ;;=I11.0^^61^806^12

 ;;^UTILITY(U,$J,358.3,18188,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18188,1,3,0)

 ;;=3^Hypertensive Heart Disease w/ Heart Failure

 ;;^UTILITY(U,$J,358.3,18188,1,4,0)

 ;;=4^I11.0

 ;;^UTILITY(U,$J,358.3,18188,2)

 ;;=^5007063

 ;;^UTILITY(U,$J,358.3,18189,0)

 ;;=I11.9^^61^806^13

 ;;^UTILITY(U,$J,358.3,18189,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18189,1,3,0)

 ;;=3^Hypertensive Heart Disease w/o Heart Failure

 ;;^UTILITY(U,$J,358.3,18189,1,4,0)

 ;;=4^I11.9

 ;;^UTILITY(U,$J,358.3,18189,2)

 ;;=^5007064

 ;;^UTILITY(U,$J,358.3,18190,0)

 ;;=I12.0^^61^806^5

 ;;^UTILITY(U,$J,358.3,18190,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18190,1,3,0)

 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD

 ;;^UTILITY(U,$J,358.3,18190,1,4,0)

 ;;=4^I12.0

 ;;^UTILITY(U,$J,358.3,18190,2)

 ;;=^5007065

 ;;^UTILITY(U,$J,358.3,18191,0)

 ;;=I12.9^^61^806^4

 ;;^UTILITY(U,$J,358.3,18191,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18191,1,3,0)

 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD

 ;;^UTILITY(U,$J,358.3,18191,1,4,0)

 ;;=4^I12.9

 ;;^UTILITY(U,$J,358.3,18191,2)

 ;;=^5007066

 ;;^UTILITY(U,$J,358.3,18192,0)

 ;;=I13.0^^61^806^8

 ;;^UTILITY(U,$J,358.3,18192,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18192,1,3,0)

 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD

 ;;^UTILITY(U,$J,358.3,18192,1,4,0)

 ;;=4^I13.0

 ;;^UTILITY(U,$J,358.3,18192,2)

 ;;=^5007067

 ;;^UTILITY(U,$J,358.3,18193,0)

 ;;=I13.10^^61^806^10

 ;;^UTILITY(U,$J,358.3,18193,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18193,1,3,0)

 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD

 ;;^UTILITY(U,$J,358.3,18193,1,4,0)

 ;;=4^I13.10

 ;;^UTILITY(U,$J,358.3,18193,2)

 ;;=^5007068

 ;;^UTILITY(U,$J,358.3,18194,0)

 ;;=I13.11^^61^806^11

 ;;^UTILITY(U,$J,358.3,18194,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18194,1,3,0)

 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD

 ;;^UTILITY(U,$J,358.3,18194,1,4,0)

 ;;=4^I13.11

 ;;^UTILITY(U,$J,358.3,18194,2)

 ;;=^5007069

 ;;^UTILITY(U,$J,358.3,18195,0)

 ;;=I13.2^^61^806^9

 ;;^UTILITY(U,$J,358.3,18195,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18195,1,3,0)

 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD

 ;;^UTILITY(U,$J,358.3,18195,1,4,0)

 ;;=4^I13.2

 ;;^UTILITY(U,$J,358.3,18195,2)

 ;;=^5007070

 ;;^UTILITY(U,$J,358.3,18196,0)

 ;;=I15.0^^61^806^15

 ;;^UTILITY(U,$J,358.3,18196,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,18196,1,3,0)

 ;;=3^Renovascular Hypertension

 ;;^UTILITY(U,$J,358.3,18196,1,4,0)

 ;;=4^I15.0

 ;;^UTILITY(U,$J,358.3,18196,2)

 ;;=^5007071

 ;;^UTILITY(U,$J,358.3,18197,0)

 ;;=I15.1^^61^806^3

--- Routine Detail   --- with STRUCTURED ROUTINE LISTING ---IBDEI14F   3791     printed  Feb 18, 2025@23:27:54                                                                                                                                                                                                    Page 2

IBDEI14F  ; ; 01-FEB-2022

 +1       ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022

 +2        if 'DIFQR(358.3)

               QUIT 

           FOR I=1:2

               SET X=$TEXT(Q+I)

               if X=""

                   QUIT 

               SET Y=$EXTRACT($TEXT(Q+I+1),4,999)

               SET X=$EXTRACT(X,4,999)

               if $ASCII(Y)=126

                   SET I=I+1

                   SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)

               if $ASCII(Y)=61

                   SET Y=$EXTRACT(Y,2,999)

               XECUTE NO

              IF '$TEST

                   SET @X=Y

Q          QUIT 

 +1       ;;^UTILITY(U,$J,358.3,18185,0)

 +2       ;;=E11.620^^61^805^5

 +3       ;;^UTILITY(U,$J,358.3,18185,1,0)

 +4       ;;=^358.31IA^4^2

 +5       ;;^UTILITY(U,$J,358.3,18185,1,3,0)

 +6       ;;=3^DM Type 2 w/ Diab Dermatitis

 +7       ;;^UTILITY(U,$J,358.3,18185,1,4,0)

 +8       ;;=4^E11.620

 +9       ;;^UTILITY(U,$J,358.3,18185,2)

 +10      ;;=^5002655

 +11      ;;^UTILITY(U,$J,358.3,18186,0)

 +12      ;;=E11.36^^61^805^4

 +13      ;;^UTILITY(U,$J,358.3,18186,1,0)

 +14      ;;=^358.31IA^4^2

 +15      ;;^UTILITY(U,$J,358.3,18186,1,3,0)

 +16      ;;=3^DM Type 2 w/ Diab Cataract

 +17      ;;^UTILITY(U,$J,358.3,18186,1,4,0)

 +18      ;;=4^E11.36

 +19      ;;^UTILITY(U,$J,358.3,18186,2)

 +20      ;;=^5002642

 +21      ;;^UTILITY(U,$J,358.3,18187,0)

 +22      ;;=I10.^^61^806^1

 +23      ;;^UTILITY(U,$J,358.3,18187,1,0)

 +24      ;;=^358.31IA^4^2

 +25      ;;^UTILITY(U,$J,358.3,18187,1,3,0)

 +26      ;;=3^Essential/Primary Hypertension

 +27      ;;^UTILITY(U,$J,358.3,18187,1,4,0)

 +28      ;;=4^I10.

 +29      ;;^UTILITY(U,$J,358.3,18187,2)

 +30      ;;=^5007062

 +31      ;;^UTILITY(U,$J,358.3,18188,0)

 +32      ;;=I11.0^^61^806^12

 +33      ;;^UTILITY(U,$J,358.3,18188,1,0)

 +34      ;;=^358.31IA^4^2

 +35      ;;^UTILITY(U,$J,358.3,18188,1,3,0)

 +36      ;;=3^Hypertensive Heart Disease w/ Heart Failure

 +37      ;;^UTILITY(U,$J,358.3,18188,1,4,0)

 +38      ;;=4^I11.0

 +39      ;;^UTILITY(U,$J,358.3,18188,2)

 +40      ;;=^5007063

 +41      ;;^UTILITY(U,$J,358.3,18189,0)

 +42      ;;=I11.9^^61^806^13

 +43      ;;^UTILITY(U,$J,358.3,18189,1,0)

 +44      ;;=^358.31IA^4^2

 +45      ;;^UTILITY(U,$J,358.3,18189,1,3,0)

 +46      ;;=3^Hypertensive Heart Disease w/o Heart Failure

 +47      ;;^UTILITY(U,$J,358.3,18189,1,4,0)

 +48      ;;=4^I11.9

 +49      ;;^UTILITY(U,$J,358.3,18189,2)

 +50      ;;=^5007064

 +51      ;;^UTILITY(U,$J,358.3,18190,0)

 +52      ;;=I12.0^^61^806^5

 +53      ;;^UTILITY(U,$J,358.3,18190,1,0)

 +54      ;;=^358.31IA^4^2

 +55      ;;^UTILITY(U,$J,358.3,18190,1,3,0)

 +56      ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD

 +57      ;;^UTILITY(U,$J,358.3,18190,1,4,0)

 +58      ;;=4^I12.0

 +59      ;;^UTILITY(U,$J,358.3,18190,2)

 +60      ;;=^5007065

 +61      ;;^UTILITY(U,$J,358.3,18191,0)

 +62      ;;=I12.9^^61^806^4

 +63      ;;^UTILITY(U,$J,358.3,18191,1,0)

 +64      ;;=^358.31IA^4^2

 +65      ;;^UTILITY(U,$J,358.3,18191,1,3,0)

 +66      ;;=3^Hypertensive CKD w/ Stage 1-4 CKD

 +67      ;;^UTILITY(U,$J,358.3,18191,1,4,0)

 +68      ;;=4^I12.9

 +69      ;;^UTILITY(U,$J,358.3,18191,2)

 +70      ;;=^5007066

 +71      ;;^UTILITY(U,$J,358.3,18192,0)

 +72      ;;=I13.0^^61^806^8

 +73      ;;^UTILITY(U,$J,358.3,18192,1,0)

 +74      ;;=^358.31IA^4^2

 +75      ;;^UTILITY(U,$J,358.3,18192,1,3,0)

 +76      ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD

 +77      ;;^UTILITY(U,$J,358.3,18192,1,4,0)

 +78      ;;=4^I13.0

 +79      ;;^UTILITY(U,$J,358.3,18192,2)

 +80      ;;=^5007067

 +81      ;;^UTILITY(U,$J,358.3,18193,0)

 +82      ;;=I13.10^^61^806^10

 +83      ;;^UTILITY(U,$J,358.3,18193,1,0)

 +84      ;;=^358.31IA^4^2

 +85      ;;^UTILITY(U,$J,358.3,18193,1,3,0)

 +86      ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD

 +87      ;;^UTILITY(U,$J,358.3,18193,1,4,0)

 +88      ;;=4^I13.10

 +89      ;;^UTILITY(U,$J,358.3,18193,2)

 +90      ;;=^5007068

 +91      ;;^UTILITY(U,$J,358.3,18194,0)

 +92      ;;=I13.11^^61^806^11

 +93      ;;^UTILITY(U,$J,358.3,18194,1,0)

 +94      ;;=^358.31IA^4^2

 +95      ;;^UTILITY(U,$J,358.3,18194,1,3,0)

 +96      ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD

 +97      ;;^UTILITY(U,$J,358.3,18194,1,4,0)

 +98      ;;=4^I13.11

 +99      ;;^UTILITY(U,$J,358.3,18194,2)

 +100     ;;=^5007069

 +101     ;;^UTILITY(U,$J,358.3,18195,0)

 +102     ;;=I13.2^^61^806^9

 +103     ;;^UTILITY(U,$J,358.3,18195,1,0)

 +104     ;;=^358.31IA^4^2

 +105     ;;^UTILITY(U,$J,358.3,18195,1,3,0)

 +106     ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD

 +107     ;;^UTILITY(U,$J,358.3,18195,1,4,0)

 +108     ;;=4^I13.2

 +109     ;;^UTILITY(U,$J,358.3,18195,2)

 +110     ;;=^5007070

 +111     ;;^UTILITY(U,$J,358.3,18196,0)

 +112     ;;=I15.0^^61^806^15

 +113     ;;^UTILITY(U,$J,358.3,18196,1,0)

 +114     ;;=^358.31IA^4^2

 +115     ;;^UTILITY(U,$J,358.3,18196,1,3,0)

 +116     ;;=3^Renovascular Hypertension

 +117     ;;^UTILITY(U,$J,358.3,18196,1,4,0)

 +118     ;;=4^I15.0

 +119     ;;^UTILITY(U,$J,358.3,18196,2)

 +120     ;;=^5007071

 +121     ;;^UTILITY(U,$J,358.3,18197,0)

 +122     ;;=I15.1^^61^806^3